Arcturus Therapeutics Holdings (ARCT) Valuation Check As J.P. Morgan Healthcare Conference Presentation Nears

Arcturus Therapeutics Holdings (ARCT) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. This event is a forum where management often outlines pipeline progress and capital priorities.

See our latest analysis for Arcturus Therapeutics Holdings.

At a share price of $7.53, Arcturus has seen an 11.06% 1 day and 13.92% 7 day share price return. Its 1 year total shareholder return of 54.61% decline and 5 year total shareholder return of 89.00% decline suggest that recent momentum contrasts with a much tougher longer term record as investors weigh the conference update against past volatility.

If this kind of catalyst driven move has your attention, it could be a good moment to widen your watchlist and look at other healthcare stocks that are catching interest.

With the stock at US$7.53, a value score of 2 and a J.P. Morgan conference spotlight ahead, is Arcturus being overlooked after large multi year declines, or is the market already pricing in future growth?

Price to Sales of 2.2x: Is it justified?

At a last close of US$7.53, Arcturus trades on a P/S of 2.2x, which screens as good value against peers but screens as expensive versus its own estimated fair ratio.

P/S compares the company’s market value with its revenue, which can be useful for loss making biotechs where earnings based ratios such as P/E are not yet meaningful.

For Arcturus, the current 2.2x P/S is described as good value compared with both its direct peer set at 6.7x and the broader US biotechs industry at 12.4x. This suggests the market assigns a lower revenue multiple than many comparables. At the same time, the company is described as expensive relative to an estimated fair P/S of 1x, a level our work suggests the market could gravitate toward if sentiment or revenue expectations change.

That mix of cheaper than peers but above an internally estimated fair ratio underlines a tension between what similar companies trade on and where this specific name might settle if pricing moved closer to that fair multiple.

Explore the SWS fair ratio for Arcturus Therapeutics Holdings

Result: Price-to-Sales of 2.2x (ABOUT RIGHT)

However, there are clear pressure points too, including ongoing net losses of US$66.709m and heavy share price declines over 3 and 5 years, which may cap enthusiasm.

Find out about the key risks to this Arcturus Therapeutics Holdings narrative.

Build Your Own Arcturus Therapeutics Holdings Narrative

If you see the story differently or simply want to test your own view against the numbers, you can build a tailored thesis in just a few minutes by starting with Do it your way.

Story Continues

A great starting point for your Arcturus Therapeutics Holdings research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Arcturus has sparked your curiosity, do not stop here. Broaden your opportunity set and let the data guide where you focus next.

Target potential mispricings by scanning these 883 undervalued stocks based on cash flows that the market may be overlooking based on cash flows and fundamentals. Ride powerful tech shifts by checking out these 25 AI penny stocks that sit at the intersection of artificial intelligence and growth potential. Position your portfolio for income by reviewing these 12 dividend stocks with yields > 3% that offer yields above 3% alongside stock market exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ARCT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments